IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IOVANCE BIOTHERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$14.21+0.59 (+4.33%)
Close on Oct 19, 2026
- Market cap
- $6.40M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$12.03 (+551.8%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
IOVANCE BIOTHERAPEUTICS, INC. grew revenue 34.5% to $324.97M over the twelve months to Jun 30, 2026. Free cash flow was -$296.40M.
Revenue
$324.97M
+34.5% vs. a year earlier
Operating income
-$301.31M
TTM Q2 2026
Free cash flow
-$296.40M
TTM Q2 2026
EPS, diluted
-$1.09
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.40M
- P/E ratio
- –
- Price to sales
- 0.02
- Price to book
- 0.01
- Dividend yield
- –
- Free cash flow yield
- -4633.21%
Fundamentals
- Revenue
- $324.97M
- Net income
- -$289.52M
- EPS, diluted
- -$1.09
- Free cash flow
- -$296.40M
- Book value per share
- $1634.97
- Diluted shares
- 0M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$324.97M+34.5% YoY
Gross profit
$157.29M+95.1% YoY
Operating income
-$301.31M
Net income
-$289.52M
EPS, diluted
–
Free cash flow
-$296.40M
Reported periodTrailing twelve months